Efalizumab: no safety concerns up to 2 years. (01-NOV-04) Skin & Allergy News

AccessMyLibrary : Search Information that Libraries Trust

AccessMyLibrary Browse S Skin & Allergy News NOV-04 Efalizumab: no safety concerns up to 2 years.(Dermatologic Therapy)

Efalizumab: no safety concerns up to 2 years.(Dermatologic Therapy)

Publication: Skin & Allergy News

Publication Date: 01-NOV-04

Author: Kirn, Timothy F.

How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.

Bookmark this article

VICTORIA, B.C. -- Pooled data from company trials of efalizumab show no safety concerns with up to 2 years of continuous use, the longest anyone has taken the drug, Charles W. Lynde, M.D., said at the annual conference of the Canadian Dermatology Association.

In 200 patients who have been on the drug for 2 years as...

Read the full article for free courtesy of your local library.

More Articles from Skin & Allergy News

Bowen's patients cleared better with metvix PDT.(Dermatologic Therapy)
November 01, 2004

Physician groups support clinical trials registry.(Practice Trends)
November 01, 2004

Appointment Scheduling.(Managing Your Dermatology Practice)
November 01, 2004

Preparing for maternity and paternity leave.(The Rest of Your Life)
November 01, 2004

California issues tanning ban.(Policy & Practice)(Brief Article)
November 01, 2004



		What's on AccessMyLibrary? 31,982,826 articles in the following categories: Arts, Business, Consumer News, Culture & Society, Education, Government, Personal Interest, Health, News, Science & Technology


	© 2008 Gale, a part of Cengage Learning	\| All Rights Reserved \| About this Service \| About The Gale Group, a part of Cengage Learning Privacy Policy \| Site Map \| Content Licensing \| Contact Us \| Link to us
		Other Gale sites: Books & Authors \| Goliath \| MovieRetriever.com \| WiseTo Social Issues